Glaxo Wellcome Lotronex
Glaxo expects approval of the irritable bowel syndrome therapy in January, firm tells Chase H&Q conference Jan. 12, although the FDA review deadline has been extended by three months to March 31. FDA requested additional safety information after the Gastrointestinal Drugs Advisory Committee expressed concern over the incidence of constipation, possible cases of ischemic colitis and use in patients with elevated liver enzyme levels (1"The Pink Sheet" Nov. 22, 1999, p. 3)
You may also be interested in...
The recommended indication for Glaxo Wellcome's irritable bowel syndrome therapy Lotronex would cover about one-third of the U.S. IBS population.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials